Stock Events

Stock Events

Genfit 

0
114
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 2026
€7.69
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Sep 28Expected
Q1 2026
Q2 2026
-0.2
-0.14
-0.09
-0.03
Expected EPS
-0.16069241023999997
Actual EPS
-0.2008655128

Financials

-131.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
65.43MRevenue
-85.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XUPB.MU. It's not an investment recommendation.
TotalEnergies
23
TTE.PA
Air Liquide
22
AI.PA
Engie
19
ENGI.PA
BNP Paribas
15
BNP.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.94B
Madrigal Pharmaceuticals is focused on developing therapies for NASH, directly competing with Genfit's NASH programs.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor to Genfit.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences has a strong pipeline in liver diseases, including NASH treatments, positioning it as a competitor to Genfit.
Agios Pharmaceuticals
AGIO
Mkt Cap1.82B
Agios Pharmaceuticals, though primarily focused on cancer and rare genetic diseases, has interests in metabolic disorders, potentially overlapping with Genfit's work.
Eocene
GLMD
Mkt Cap4.14M
Galmed Pharmaceuticals is developing therapies for liver diseases, including NASH, competing in the same space as Genfit.
Axsome Therapeutics
AXSM
Mkt Cap7.57B
Axsome Therapeutics, primarily focused on CNS disorders, has a broader portfolio that could intersect with metabolic diseases treatment, indirectly competing with Genfit.

About

Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
Show More
CEO
Pascal Prigent
Employees
180
Country
France
ISIN
US3722791098
WKN
000A2PFG5

Listings

MU
DE
XUP.MU
STU
DE
XUP.STU
F
DE
XUP.F
XETRA
DE
XUP.XETRA

0 Comments

Share your thoughts

FAQs

What is Genfit stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Genfit stocks are traded under the ticker XUPB.MU.
When is the next Genfit earnings date?▼
Genfit is going to release the next earnings report on April 8, 2027.
What were Genfit earnings last quarter?▼
XUPB.MU earnings for the last quarter are -0.2 EUR per share, whereas the estimation was -0.16 EUR resulting in a -25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Genfit revenue for the last year?▼
Genfit revenue for the last year amounts to 65.43M EUR.
What is Genfit net income for the last year?▼
XUPB.MU net income for the last year is -85.97M EUR.
Does Genfit pay dividends?▼
Yes, XUPB.MU dividends are paid en. The last dividend per share was 7.69 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Genfit have?▼
As of November 6, 2026, the company has 180 employees.
In which sector is Genfit located?▼
Genfit operates in the Health & Wellness sector.
When did Genfit complete a stock split?▼
Genfit has not had any recent stock splits.
Where is Genfit headquartered?▼
Genfit is headquartered in Loos, France.